| Dr Cosmina Cristea, DO | |
|
3500 Franciscan Way Ste 3a, Michigan City, IN 46360-0021 | |
| (219) 861-8828 | |
| (219) 861-8827 |
| Full Name | Dr Cosmina Cristea |
|---|---|
| Gender | Female |
| Speciality | Surgery |
| Location | 3500 Franciscan Way Ste 3a, Michigan City, Indiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891221594 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 02006778A (Indiana) | Primary |
| Entity Name | Indiana Surgical Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679616296 PECOS PAC ID: 2163415621 Enrollment ID: O20040408000514 |
News Archive
Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.
September brings warmer weather, new blooms and lots of pollen which can seriously affect people managing asthma.
Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced a strategic alliance agreement with the University of Pretoria as part of its industry unique Prime Site program, an initiative to accelerate the development of new and more effective medicines.
The US Food and Drug Administration has granted marketing approval to GlaxoSmithKline's new type 2 diabetes drug, branded Tanzeum in the US and Eperzan in Europe, which uses Novozymes' Veltis technology to achieve an extended half-life that means patients are only required to inject their medication once a week.
CMC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and River Vision Development Corporation (River Vision), a private company focused on ophthalmology, announced today that they have entered into an agreement for the process transfer and cGMP production of RV001 (Teprotumumab) – a recombinant monoclonal antibody targeting insulin-like growth factor 1 that is in development for treatment of Grave's Orbitopathy and other indications.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Cosmina Cristea, DO 7895 Grand Blvd, Hobart, IN 46342-6665 Ph: (219) 947-1910 | Dr Cosmina Cristea, DO 3500 Franciscan Way Ste 3a, Michigan City, IN 46360-0021 Ph: (219) 861-8828 |
News Archive
Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.
September brings warmer weather, new blooms and lots of pollen which can seriously affect people managing asthma.
Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced a strategic alliance agreement with the University of Pretoria as part of its industry unique Prime Site program, an initiative to accelerate the development of new and more effective medicines.
The US Food and Drug Administration has granted marketing approval to GlaxoSmithKline's new type 2 diabetes drug, branded Tanzeum in the US and Eperzan in Europe, which uses Novozymes' Veltis technology to achieve an extended half-life that means patients are only required to inject their medication once a week.
CMC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and River Vision Development Corporation (River Vision), a private company focused on ophthalmology, announced today that they have entered into an agreement for the process transfer and cGMP production of RV001 (Teprotumumab) – a recombinant monoclonal antibody targeting insulin-like growth factor 1 that is in development for treatment of Grave's Orbitopathy and other indications.
› Verified 3 days ago
Aaron Joseph Schneider, MD Surgery Medicare: Medicare Enrolled Practice Location: 3500 Franciscan Way Ste 3a, Michigan City, IN 46360 Phone: 219-861-8828 Fax: 219-861-8827 | |
Matthew G Troy, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 3500 Franciscan Way Ste 300, Michigan City, IN 46360 Phone: 219-879-6531 Fax: 219-878-8331 | |
Virginia Santos Newman, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 8865 W 400 N, Suite 175, Michigan City, IN 46360 Phone: 219-877-2225 Fax: 219-877-2230 | |
Danny C Sardon, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 1507 Wabash St, Suite 400b, Michigan City, IN 46360 Phone: 219-872-7555 Fax: 855-774-1402 | |
Bruce J Stoehr Jr., MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1507 Wabash St Ste 400d, Michigan City, IN 46360 Phone: 219-861-8828 Fax: 219-861-8827 | |
Charles W Tattersall, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 8865 W 400 N Ste 175, Michigan City, IN 46360 Phone: 219-877-2225 Fax: 219-877-2230 |